908 Devices Inc.
MASS
NASDAQ·Healthcare·Medical - Specialties·Mkt cap $412.3M
$10.05
▲ +0.10%
P/E
-10.58
Mkt Cap
$412.3M
52-Wk Range
$5.03–$11.25
52-Week Range
$5.03 - $11.25
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 78.2% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary miniaturized mass spectrometry technology enabling portable, battery-powered devices
- Purpose-built solutions for specific applications reducing complexity versus general-purpose instruments
- Real-time analytical capabilities for bioprocessing optimization and quality control
- Plug-and-play platform design reducing implementation barriers and customer adoption
Bear Case
1 risk
- Low volatility (beta 0.7).
Growth
Moderate growth ahead
Increasing demand for real-time bioprocess monitoring in pharmaceutical manufacturing
Value
Deep value opportunity - significant discount to Medical Devices peers
Momentum
Hot
+24.1% over 3m
Quality
Strong
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying MASS right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 9, 2026
AUG 11, 2026
Reported EPS of -$0.11 vs -$0.14 consensus (+22.5% surprise). Revenue of $16.1M vs $15.4M expected (+4.5%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+22.5%
Revenue trend · last 8Q
—
+31%
+59%
+14%
-4%
-8%
+14%
+23%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$14.5M
$18.8M
$11.8M
$13.0M
$14.0M
$17.4M
$13.4M
$16.1M
Margins · last 8Q
Gross
51.9%
Operating
-79.7%
Profit
-74.0%
Wall Street consensus
1 analyst · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Roth Capital · Aug 12, 2026
vs Industry
How MASS stacks vs Medical - Specialties
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related